Opaleye Management
Latest statistics and disclosures from Opaleye Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are HROW, LQDA, ETON, SLGL, RYTM, and represent 44.02% of Opaleye Management's stock portfolio.
- Added to shares of these 10 stocks: URGN (+$21M), MGTX (+$15M), CATX (+$15M), IRON (+$14M), QTTB (+$6.7M), ASRT (+$5.1M), EDIT, LQDA, SLGL, BDSX.
- Started 10 new stock positions in FDMT, EDIT, LYEL, BBOT, BDSX, NXTC, ASRT, NTLA, Perspective Therapeutics, LBRX.
- Reduced shares in these 10 stocks: RYTM (-$59M), HROW (-$38M), CGON (-$21M), , GOSS (-$8.4M), OCUL (-$8.4M), KPTI (-$6.8M), PLX, ZYME, TECX.
- Sold out of its positions in Assertio Holdings, BBIO, GBIO, GOSS, KPTI, RAPT, SLN, VTYX, ZYME, ALKS.
- Opaleye Management was a net seller of stock by $-68M.
- Opaleye Management has $759M in assets under management (AUM), dropping by 0.18%.
- Central Index Key (CIK): 0001595855
Tip: Access up to 7 years of quarterly data
Positions held by Opaleye Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Opaleye Management
Opaleye Management holds 54 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Harrow Health (HROW) | 13.2 | $100M | -27% | 2.8M | 35.26 |
|
| Liquidia Corporation Com New (LQDA) | 11.7 | $89M | +4% | 2.5M | 34.90 |
|
| Eton Pharmaceuticals (ETON) | 9.3 | $71M | 2.9M | 24.68 |
|
|
| Sol-gel Technologies Shs New (SLGL) | 5.2 | $40M | +10% | 500k | 79.22 |
|
| Rhythm Pharmaceuticals (RYTM) | 4.7 | $35M | -62% | 123k | 287.18 |
|
| Apogee Therapeutics (APGE) | 4.3 | $33M | 390k | 84.17 |
|
|
| Disc Medicine (IRON) | 3.5 | $27M | +110% | 421k | 63.94 |
|
| Urogen Pharma (URGN) | 3.4 | $26M | +432% | 1.4M | 17.98 |
|
| Crescent Biopharma (CBIO) | 3.2 | $24M | +11% | 1.3M | 18.37 |
|
| Stoke Therapeutics (STOK) | 3.0 | $23M | 700k | 32.56 |
|
|
| Perspective Therapeutics Com New (CATX) | 2.6 | $20M | +294% | 4.7M | 4.17 |
|
| Rezolute Com New (RZLT) | 2.5 | $19M | 6.3M | 3.05 |
|
|
| Meiragtx Holdings (MGTX) | 2.4 | $18M | +443% | 2.1M | 8.66 |
|
| Tg Therapeutics (TGTX) | 2.3 | $18M | 535k | 33.22 |
|
|
| Sanuwave Health (SNWV) | 2.2 | $17M | 981k | 17.29 |
|
|
| Edgewise Therapeutics (EWTX) | 2.1 | $16M | 500k | 31.50 |
|
|
| Alpha Cognition Com New (ACOG) | 1.9 | $14M | +23% | 2.6M | 5.49 |
|
| Annexon (ANNX) | 1.7 | $13M | -10% | 2.3M | 5.54 |
|
| Alumis (ALMS) | 1.6 | $12M | +2% | 550k | 22.03 |
|
| Codexis (CDXS) | 1.5 | $11M | 6.8M | 1.63 |
|
|
| Protagonist Therapeutics (PTGX) | 1.4 | $11M | -4% | 100k | 105.40 |
|
| Revolution Medicines (RVMD) | 1.3 | $9.7M | 100k | 97.25 |
|
|
| Xoma Royalty Corporation Com New (XOMA) | 1.2 | $9.4M | +2% | 300k | 31.37 |
|
| Q32 Bio (QTTB) | 1.1 | $8.1M | +488% | 1.3M | 6.42 |
|
| Mbx Biosciences (MBX) | 1.0 | $7.8M | 260k | 29.85 |
|
|
| Relmada Therapeutics (RLMD) | 0.9 | $6.5M | 935k | 6.96 |
|
|
| Cg Oncology (CGON) | 0.8 | $6.4M | -76% | 95k | 67.68 |
|
| Jade Biosciences Com New (JBIO) | 0.8 | $6.0M | 428k | 14.05 |
|
|
| Ocular Therapeutix (OCUL) | 0.7 | $5.1M | -62% | 600k | 8.47 |
|
| Assertio Holdings Com New (ASRT) | 0.7 | $5.1M | NEW | 266k | 19.06 |
|
| Editas Medicine (EDIT) | 0.6 | $4.8M | NEW | 1.9M | 2.47 |
|
| Sutro Biopharma Com Shs (STRO) | 0.6 | $4.7M | 191k | 24.91 |
|
|
| Journey Med Corp (DERM) | 0.6 | $4.5M | 960k | 4.69 |
|
|
| Voyager Therapeutics (VYGR) | 0.6 | $4.4M | -3% | 1.2M | 3.86 |
|
| Trevi Therapeutics (TRVI) | 0.5 | $4.1M | 345k | 11.93 |
|
|
| Tectonic Therapeutic (TECX) | 0.5 | $3.8M | -42% | 123k | 30.91 |
|
| Cabaletta Bio (CABA) | 0.5 | $3.7M | +53% | 1.4M | 2.69 |
|
| Biodesix (BDSX) | 0.5 | $3.5M | NEW | 238k | 14.50 |
|
| Rocket Pharmaceuticals (RCKT) | 0.5 | $3.4M | 955k | 3.58 |
|
|
| Zentalis Pharmaceuticals (ZNTL) | 0.4 | $3.3M | 1.4M | 2.34 |
|
|
| Intellia Therapeutics (NTLA) | 0.4 | $3.1M | NEW | 245k | 12.82 |
|
| Fortress Biotech Com New (FBIO) | 0.4 | $2.9M | -4% | 1.0M | 2.79 |
|
| Ocuphire Pharma (IRD) | 0.3 | $2.3M | 1.1M | 2.01 |
|
|
| Rigel Pharmaceuticals (RIGL) | 0.2 | $1.9M | 70k | 27.04 |
|
|
| Atea Pharmaceuticals (AVIR) | 0.2 | $1.7M | +79% | 323k | 5.38 |
|
| Lyell Immunopharma Com New (LYEL) | 0.2 | $1.6M | NEW | 79k | 20.06 |
|
| Enanta Pharmaceuticals (ENTA) | 0.2 | $1.6M | +66% | 125k | 12.63 |
|
| Nextcure Com New (NXTC) | 0.2 | $1.5M | NEW | 141k | 10.68 |
|
| 4d Molecular Therapeutics In (FDMT) | 0.1 | $1.0M | NEW | 112k | 9.31 |
|
| Perspective Therapeutics Call | 0.1 | $834k | NEW | 200k | 4.17 |
|
| Protalix Biotherapeutics (PLX) | 0.1 | $738k | -86% | 340k | 2.17 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.1 | $477k | NEW | 53k | 8.95 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 0.0 | $358k | NEW | 15k | 24.66 |
|
| Adagio Med Hldgs (ADGM) | 0.0 | $21k | 18k | 1.15 |
|
Past Filings by Opaleye Management
SEC 13F filings are viewable for Opaleye Management going back to 2013
- Opaleye Management 2026 Q1 filed May 15, 2026
- Opaleye Management 2025 Q4 restated filed April 13, 2026
- Opaleye Management 2025 Q4 filed Feb. 17, 2026
- Opaleye Management 2025 Q3 filed Nov. 14, 2025
- Opaleye Management 2025 Q2 restated filed Aug. 15, 2025
- Opaleye Management 2025 Q1 filed May 15, 2025
- Opaleye Management 2024 Q4 filed Feb. 14, 2025
- Opaleye Management 2024 Q3 filed Nov. 14, 2024
- Opaleye Management 2024 Q2 filed Aug. 14, 2024
- Opaleye Management 2024 Q1 restated filed May 29, 2024
- Opaleye Management 2024 Q1 filed May 15, 2024
- Opaleye Management 2023 Q4 filed Feb. 14, 2024
- Opaleye Management 2023 Q3 filed Nov. 15, 2023
- Opaleye Management 2023 Q2 filed Aug. 14, 2023
- Opaleye Management 2023 Q1 filed May 15, 2023
- Opaleye Management 2022 Q4 filed Feb. 10, 2023